Synpromics was nominated on the strength of being the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design.
The OBN Awards celebrate innovation and outstanding achievement across the UK Life Sciences industry, including emerging to late-stage R&D companies as well as life science investors. The Awards cover biotech, medtech, synthetic biology and digital health.
Receiving the award, Michael Roberts, founder and CSO of Synpromics, commented: “We could not be happier with the outcome of last night’s Awards.”
“This accolade is testament to the significant progress we have made over the past year, in growing our business by expanding the number of partnerships that we have with top pharma and biotech companies and significantly expanding our team.”
Synpromics would like to thank OBN for organising The Awards, and SynbiCITE for sponsoring this award.